Immune response to MVA85A or placebo in BCG-vaccinated South African infants at days 0 and 28 post-vaccination

ABSTRACT: Background: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in BCG-vaccinated infants were published last year. Although no improvement in efficacy above BCG alone was seen, cryopreserved samples from this trial provide an opportunity to study the immune response to vaccination in this population. Methods: We investigated blood samples taken before vaccination (baseline) and one and 28 days post-vaccination with MVA85A or placebo (Candin). The IFN-γ ELISpot assay was performed at baseline and on day 28 to quantify the adaptive response to Ag85A peptides. Gene expression analysis was performed at all three timepoints to

ORGANISM(S): Homo sapiens

SUBMITTER: Magali Matsumiya 

PROVIDER: E-GEOD-56561 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress